Skip to main content
Fig. 7 | Breast Cancer Research

Fig. 7

From: Cellular dormancy in minimal residual disease following targeted therapy

Fig. 7

Residual disease is enriched for rare tumor cell subpopulations present in primary tumors. a Flow cytometry for EpCAM and CD49e on YFP+CD45−DAPI− singlet tumor cells in MTB;TetO-HER2/neu;TTC;rYFP primary tumor cells (left) or dormant residual tumor cells (right). b, c Flow cytometry on populations in (a) for CD24 and PDGFR-β expression on CD49e−EpCAM+ primary tumor cells (b) or CD49e+EpCAM− residual tumor cells (c). d Quantification of percent CD49e−EpCAM+ or CD49e+EpCAM− tumor cells in primary tumors or residual lesions, using gates from (a), in MTB;TetO-HER2/neu;TTC;rYFP mice. e Limiting dilution assay of CD24+Thy1+ tumor cells, or non-CD24+Thy1+ tumor cells, from MTB;TetO-Wnt1;TTC;rYFP primary tumors. f Flow cytometry for CD24 and Thy1 expression on YFP+CD45−DAPI− singlet tumor cells in MTB;TetO-Wnt1;TTC;rYFP primary tumor cells (left) or residual tumor cells (right). g Quantification of percent CD24+Thy1+ or non-CD24+Thy1+ tumor cells in primary tumors or residual lesions, using gates from f, in MTB;TetO-Wnt1;TTC;rYFP mice. **p value vs. primary tumor (PT) < 0.01, ***p value vs. PT < 0.001

Back to article page